

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 45

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 45

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 45

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

Latin, English, French, Spanish:

Recommended INN Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

adekalantum

adekalant

tert-butyl 7-[(*S*)-3-(*p*-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate


adékalant

7-[(2*S*)-3-(4-cyanophénoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate de 1,1-diméthyléthyle

adekalant

7-[(*S*)-3-(*p*-cianofenoxi)-2-hidroxipropil]-3,7-diazabicyclo[3.3.1]nonano-3-carboxilato de *tert*-butilo

C₂₂H₃₁N₃O₄



alemtuzumabum

alemtuzumab

immunoglobulin G 1 (human-rat monoclonal CAMPATH-1H γ 1-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer

alemtuzumab

immunoglobuline G1 anti-(antigène CD52 humain) (chaîne γ 1 de l'anticorps monoclonal de rat CAMPATH-1H humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat CAMPATH-1H humanisé

alemtuzumab

inmunoglobulina G 1 anti-(antígeno humano CD52) (cadena γ 1 del anticuerpo monoclonal hombre-rata CAMPATH-1H), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal hombre-rata CAMPATH-1H

aliskirenum


aliskiren

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide

aliskirène

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(3-amino-2,2-diméthyl-3-oxopropyl)-4-hydroxy-7-[4-méthoxy-3-(3-méthoxypropoxy)benzyl]-8-méthyl-2-(1-méthyléthyl)nonanamide

aliskireno

(2*S*,4*S*,5*S*,7*S*)-5-amino-*N*-(2-carbamoil-2-metilpropil)-4-hidroxi-2-isopropil-7-[4-metoxi-3-(3-metoxipropoxi)benzil]-8-metilnonanamidaC₃₀H₅₃N₃O₅**amiloxatum**


amiloxate

isopentyl *p*-methoxycinnamate

amiloxate

(E)-3-(4-méthoxyphényl)prop-2-énoate de 3-méthylbutyle

amiloxato

p-metoxicinamato de isopentiloC₁₅H₂₀O₃**bevacizumabum**

bevacizumab

immunoglobulin G 1 (human-mouse monoclonal rhuMAb-VEGF γ -chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMAb-VEGF light chain, dimer



bévacizumab

immunoglobuline G1 anti-(facteur de croissance de l'endothélium vasculaire humain) (chaîne γ 1 de l'anticorps monoclonal de souris rhuMAb-VEGF humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris rhuMAb-VEGF humanisé

bevacizumab



inmunoglobulina G 1 anti-(factor de crecimiento del endotelio vascular humano) (cadena γ 1 del anticuerpo monoclonal hombre ratón rhuMAb-VEGF), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal hombre-ratón rhuMAb-VEGFC₆₆₃₈H₁₀₁₆₀N₁₇₂₀O₂₁₀₈S₄₄

biotinum	
biotin	5-[(3a <i>S</i> ,4 <i>S</i> ,6a <i>R</i>)-2-oxohexahydro-1 <i>H</i> -thieno[3,4- <i>d</i>]imidazol-4-yl]pentanoic acid
biotine	acide 5-[(3a <i>S</i> ,4 <i>S</i> ,6a <i>R</i>)-2-oxohexahydro-1 <i>H</i> -thiéno[3,4- <i>d</i>]imidazol-4-yl]pentanoïque
biotina	ácido 5-[(3a <i>S</i> ,4 <i>S</i> ,6a <i>R</i>)-2-oxohexahidro-1 <i>H</i> -tieno[3,4- <i>d</i>]imidazol-4-il]pentanoico




bivatuzumabum	
bivatuzumab	immunoglobulin G 1 (human-mouse monoclonal BIWA4 γ 1-chain anti-human antigen CD44v8), disulfide with human-mouse monoclonal BIWA4 κ -chain, dimer
bivatuzumab	immunoglobuline G1 anti-(antigène CD44v8 humain) (chaîne γ 1 de l'anticorps monoclonal de souris BIWA4 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris BIWA4 humanisé
bivatuzumab	immunoglobulina G 1 anti-(antígeno humano CD44v8) cadena γ 1 del anticuerpo monoclonal hombre-ratón BIWA4), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón BIWA4


capravirinum	
capravirine	5-[(3,5-dichlorophenyl)thio]-4-isopropyl-1-(4-pyridylmethyl)imidazole-2-methanol carbamate (ester)
capravirine	carbamate de [5-[(3,5-dichlorophényl)sulfanyl]-4-(1-méthyléthyl)-1-(pyridin-4-ylméthyl)-1 <i>H</i> -imidazol-2-yl]méthyle
capravirina	carbamato (éster)de 5-[(3,5-diclorofenil)tio]-4-isopropil-1-(4-piridilmetil)imidazol-2-metanol





capmorelinum capmorelin	2-amino- <i>N</i> -[(1 <i>R</i>)-1-[[[(3 <i>aR</i>)-3 <i>a</i> -benzyl-2,3,3 <i>a</i> ,4,6,7-hexahydro-2-methyl-3-oxo-5 <i>H</i> -pyrazolo[4,3- <i>c</i>]pyridin-5-yl]carbonyl]-2-(benzyloxy)ethyl]-2-methylpropanamide
capmoreline	2-amino- <i>N</i> -[(1 <i>R</i>)-2-[(3 <i>aR</i>)-3 <i>a</i> -benzyl-2-méthyl-3-oxo-2,3,3 <i>a</i> ,4,6,7-hexahydro-5 <i>H</i> -pyrazolo[4,3- <i>c</i>]pyridin-5-yl]-1-[(benzyloxy)méthyl]-2-oxoéthyl]-2-méthylpropanamide
capmorelina	2-amino- <i>N</i> -[(1 <i>R</i>)-1-[[[(3 <i>aR</i>)-3 <i>a</i> -bencil-2,3,3 <i>a</i> ,4,6,7-hexahidro-2-metil-3-oxo-5 <i>H</i> -pirazolo[4,3- <i>c</i>]piridin-5-il]carbonil]-2-(benciloxi)etil]-2-metilpropanamida
	$C_{28}H_{35}N_5O_4$



cridanimodum cridanimod	9-oxo-10-acridanacetic acid
cridanimod	acide (9-oxoacridin-10(9 <i>H</i>)-yl)acétique
cridanimod	ácido 9-oxo-10-acridanacético
	$C_{15}H_{11}NO_3$



doripenemum doripenem	(+)-(4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-[(1 <i>R</i>)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3 <i>S</i> ,5 <i>S</i>)-5-[(sulfamoylamino)méthyl]-3-pyrrolidinyl]thio]-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylic acid
doripénem	(+)-acide (4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-[(1 <i>R</i>)-1-hydroxyéthyl]-4-méthyl-7-oxo-3-[[[(3 <i>S</i> ,5 <i>S</i>)-5-[(aminosulfonylamino)méthyl]pyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique
doripenem	ácido (+)-(4 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-[(1 <i>R</i>)-1-hidroxietyl]-4-metil-7-oxo-3-[[[(3 <i>S</i> ,5 <i>S</i>)-5-[(sulfamoilamino)metil]-3-pirrolidinil]tio]-1-azabicyclo[3.2.0]hept-2-eno-2-carboxílico

**ecraprostum**



ecraprost

butyl (4*R*,5*R*)-2,4-dihydroxy-5-[(1*E*,3*S*)-3-hydroxy-1-octenyl]-1-cyclopentene-1-heptanoate, 2-butyrate

écraprost

7-[(4*R*,5*R*)-2-(butanoyloxy)-4-hydroxy-5-[(1*E*,3*S*)-3-hydroxyoct-1-ényl]cyclopent-1-ényl]heptanoate de butyle

ecraprost

2-butirato de (4*R*,5*R*)-2,4-dihidroxi-5-[(1*E*,3*S*)-3-hidroxi-1-octenil]-1-ciclopenteno-1-heptanoato de butilo**elarofibanum**



elarofiban

(S)-β-[(*R*)-1-[3-(4-piperidyl)propionyl]nipecotamido]-3-pyridinepropionic acid


élarofiban

acide (3*S*)-3-[[[(3*R*)-1-[3-(pipéridin-4-yl)propanoyl]piperidin-3-yl]carbonyl]amino]-3-(pyridin-3-yl)propanoïque


elarofibán

ácido (S)-β-[(*R*)-1-[3-(4-piperidil)propionil]nipecotamido]-3-piridinapropiónico


ensulizolum	
ensulizole	2-phenyl-5-benzimidazolesulfonic acid
ensulizole	acide 2-phényl-1 <i>H</i> -benzimidazole-5-sulfonique
ensulizol	ácido 2-fenil-5-bencimidazolsulfónico

C₁₃H₁₀N₂O₃S

enzacamenum	
enzacamene	(±)-3-(<i>p</i> -methylbenzylidene)camphor
enzacamène	(<i>E</i>)-(1 <i>RS</i> ,4 <i>SR</i>)-1,7,7-triméthyl-3-(4-méthylbenzylidène)bicyclo[2.2.1]heptan-2-one
enzacameno	1,7,7-trimetil-3-(4-metilbencilideno)biciclo[2.2.1]heptan-2-ona

C₁₈H₂₂O

eptaplatinum	
eptaplátin	<i>cis</i> -[[4 <i>R</i> ,5 <i>R</i>]-2-isopropyl-1,3-dioxolane-4,5-bis(méthylamine)- <i>N,N'</i>][malonato(2-)- <i>O,O'</i>]platine
eptaplátine	(<i>SP</i> -4-2)-[[4 <i>R</i> ,5 <i>R</i>]-2-(1-méthyléthyl)-1,3-dioxolane-4,5-diyl]bis(méthanamine)- <i>N,N'</i>][propanedioato(2-)- <i>O,O'</i>]platine
eptaplátino	<i>cis</i> -[[4 <i>R</i> ,5 <i>R</i>]-2-isopropil-1,3-dioxolano-4,5-bis(metilamina)- <i>N,N'</i>][malonato(2-)- <i>O,O'</i>]platino

C₁₁H₂₃N₂O₆Pt

ezetimibum


ezetimibe

(3*R*,4*S*)-1-(*p*-fluorophenyl)-3-[(3*S*)-3-(*p*-fluorophenyl)-3-hydroxypropyl]-4-(*p*-hydroxyphenyl)-2-azetidinone

ézetimibe

(3*R*,4*S*)-1-(4-fluorophényl)-3-[(3*S*)-3-(4-fluorophényl)-3-hydroxypropyl]-4-(4-hydroxyphényl)azétidin-2-one

ezetimiba

(3*R*,4*S*)-1-(*p*-fluorofenil)-3-[(3*S*)-3-(*p*-fluorofenil)-3-hidroxiopropil]-4-(*p*-hidroxiifenil)-2-azetidinonaC₂₄H₂₁F₂NO₃**fondaparinuxum natricum**

fondaparinux sodium


methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranoside, decasodium salt

fondaparinux sodique


O-6-O-sulfo-2-(sulfoamino)-2-désoxy-α-D-glucopyranosyl-(1→4)-O-β-D-glucopyranuronosyl-(1→4)-O-3,6-di-O-sulfo-2-(sulfoamino)-2-désoxy-α-D-glucopyranosyl-(1→4)-O-2-O-sulfo-α-L-idopyranuronosyl-(1→4)-6-O-sulfo-2-(sulfoamino)-2-désoxy-α-D-glucopyranoside de méthyle décasodique

fondaparinux sódico


sal decasódica del O-2-desoxi-6-O-sulfo-2-(sulfoamino)-α-D-glucopiranosil-(1→4)-O-β-D-glucopiranosil-(1→4)-O-2-desoxi-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopiranosil-(1→4)-O-2-O-sulfo-α-L-idopirauranosil-(1→4)-2-desoxi-6-O-sulfo-2-(sulfoamino)-α-D-glucopiranosido de metilo

C₃₁H₄₃N₃Na₁₀O₄₉S₈



fosamprenavirum fosamprenavir	(3S)-tetrahydro-3-furyl [(αS)-α-[(1R)-1-hydroxy-2-(N ¹ -isobutylsulfanilamido)=ethyl] phenethyl]carbamate, dihydrogen phosphate (ester)
fosamprénavir	dihydrogénophosphate de (1R,2S)-1-[[[(4-aminophényl)sulfonyl](2-méthylpropyl)amino]méthyl]-3-phényl-2-[[[(3S)-tétrahydrofuran-3-yl]oxy]=carbonyl]amino] propyle
fosamprenavir	dihidrógenofosfato (éster) de [(αS)-α-[(1R)-1-hidroxi-2-(N ¹ -isobutilsulfaniilamido)etil]fenetil]carbamato de(3S)-tetrahidro-3-furilo
	C ₂₅ H ₃₆ N ₃ O ₉ PS



fosfluconazolom fosfluconazole	2,4-difluoro-α,α-bis(1 <i>H</i> -1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)
fosfluconazole	dihydrogénophosphate de 1-(2,4-difluorophényl)-2-(1 <i>H</i> -1,2,4-triazol-1-yl)-1-(1 <i>H</i> -1,2,4-triazol-1-ylméthyl)éthyle
fosfluconazol	dihidrógenofosfato (éster) de 2,4-difluoro-α,α-bis(1 <i>H</i> -1,2,4-triazol-1-ilmetil) bencilo
	C ₁₃ H ₁₃ F ₂ N ₆ O ₄ P



fosvesetum fosveset	<i>N</i> -[2-[bis(carboxymethyl)amino]ethyl]- <i>N</i> -[(<i>R</i>)-2-[bis(carboxymethyl)amino]-3-hydroxypropyl]glycine, 4,4-diphenylcyclohexyl hydrogen phosphate (ester)
fosvését	acide 2,2'-[[[(1R)-1-[[[2-[bis(carboxyméthyl)amino]éthyl](carboxyméthyl)amino]méthyl]-2-[[[(4,4-diphénylcyclohexyl)oxy]hydroxyphosphoryl]oxy]éthyl]imino] diacétique
fosveset	4,4-difenilciclohexilhidrógenofosfato (éster) de <i>N</i> -[2-[bis(carboximetil)amino]etil]- <i>N</i> -[(<i>R</i>)-2-[bis(carboximetil)amino]-3-hidroxiopropil]glicina



gadofosvesetum
gadofosveset


trihydrogén [N-[2-[bis(carboxymethyl)amino]ethyl]-N-(R)-2-[bis(carboxymethyl)amino]-3-hydroxypropyl]glycine 4,4-diphénylcyclohexyl hydrogén phosphato(6-)]gadolinato(3-)

gadofosvéset

trihidrogéno[2,2'-[[[(1R)-1-[[[2-[bis[(carboxy-κ-O)méthyl]amino-κ-N]éthyl]=[carboxy-κ-O)méthyl]amino-κ-N]méthyl]-2-[[[(4,4-diphénylcyclohexyl)oxy]=hydroxyphosphoryl]oxy]éthyl]imino-κ-N]diacétato(6-)-κ-O-κ-O]gadolinato(3-)

gadofosveset

[4,4-difenilciclohexilhidrógenofosfato de (6-)-N-[2-[bis(carboximetil)amino]=etil]-N-[(R)-2-[bis(carboximetil)amino]-3-hidroxiopropil]glicina]gadolinato(3-) de trihidrógeno



gemtuzumabum
gemtuzumab

immunoglobulin G 4 (human-mouse monoclonal hP67.6 γ4-chain anti-human antigen CD 33), disulfide with human-mouse monoclonal hP67.6 κ-chain, dimer

gemtuzumab

immunoglobuline G 4 anti-(antigène CD 33 humain) (chaîne γ4 de l'anticorps monoclonal de souris hP67.6 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris hP67.6 humanisé

gemtuzumab

inmunoglobulina G 4 anti-(antígeno humano CD 33) (cadena γ4 del anticuerpo monoclonal hP67.6 hombre-ratón), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hP67.6 hombre-ratón

idraparinixum natricum

idraparinix sodium


methyl *O*-2,3,4-tri-*O*-methyl-6-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-methyl- β -D-glucopyranuronosyl-(1 \rightarrow 4)-*O*-2,3,6-tri-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-methyl- α -L-idopyranuronosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-sulfo- α -D-glucopyranoside nonasodium

idraparinix sodique

O-2,3,4-tri-*O*-méthyl-6-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-méthyl- β -D-glucopyranuronosyl-(1 \rightarrow 4)-*O*-2,3,6-tri-*O*-sulfo- α -D-glucopyranosyl-(1 \rightarrow 4)-*O*-2,3-di-*O*-méthyl- α -L-idopyranuronosyl-(1 \rightarrow 4)-2,3,6-tri-*O*-sulfo- α -D-glucopyranoside de méthyle nonasodique

idraparinix sódico

O-2,3,4-tri-*O*-metil-6-*O*-sulfo- α -D-glucopiranosil-(1 \rightarrow 4)-*O*-2,3-di-*O*-metil- β -D-glucopiranosil-(1 \rightarrow 4)-*O*-2,3,6-tri-*O*-sulfo- α -D-glucopiranosil-(1 \rightarrow 4)-*O*-2,3-di-*O*-metil- α -L-idopiranosil-(1 \rightarrow 4)-2,3,6-tri-*O*-sulfo- α -D-glucopiranosido de metilo nonasódico

C₃₈H₅₅Na₉O₄₉S₇**isatoribinum**


isatoribine

5-amino-3-(β -D-ribofuranosyl)thiazolo[4,5-*d*]pyrimidine-2,7(3*H*,6*H*)-dione

isatoribine

5-amino-3-(β -D-ribofuranosyl)thiazolo[4,5-*d*]pyrimidine-2,7(3*H*,6*H*)-dione

isatoribina

5-amino-3- β -D-ribofuranosiltiazolo[4,5-*d*]pirimidina-2,7(3*H*,6*H*)-dionaC₁₀H₁₂N₄O₆S

labradimilum

labradimil


*N*²-[(*S*)-2-[L-arginyl-L-prolyl-*trans*-4-hydroxy-L-prolyl]glycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido]-3-(*p*-methoxyphenyl)propyl]-L-arginine

labradimil

*N*²-[(2*S*)-2-[[L-arginyl-L-prolyl-[(4*R*)-4-hydroxy-L-prolyl]-glycyl-3-(thiophén-2-yl)-L-alanyl]-L-seryl-L-prolyl]amino]-3-(4-méthoxyphényl)propyl]-L-arginine

labradimil

*N*²-[(*S*)-2-[L-arginil-L-prolil-*trans*-4-hidroxi-L-proli]lglicil-3-(2-tienil)-L-alanil-L-seril-L-prolinamido]-3-(*p*-metoxifenil)propil]-L-arginina

C₄₉H₇₅N₁₅O₁₂S**ladirubicinum**

ladirubicin


(1*S*,3*S*)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthaceny] 3-(1-aziridinyl)-2,3,6-trideoxy-4-O-(methylsulfonyl)- α -L-lyxo-hexopyranoside

ladirubicine

(7*S*,9*S*)-9-acétyl-7-[[3-(aziridin-1-yl)-4-O-(méthylsulfonyl)-2,3,6-tridésoxy- α -L-lyxo-hexopyranosyl]oxy]-6,9,11-trihydroxy-7,8,9,10-tétrahydratétracène-5,12-dione

ladirubicina

(1*S*,3*S*)-3-acetil-1,2,3,4,6,11-hexahidro-3,5,12-trihidroxi-6,11-dioxo-1-naftaceni] 3-(1-aziridinil)-2,3,6-tridesoxi-4-O-(metilsulfonil)- α -L-lyxo-hexopiranósido

C₂₉H₃₁NO₁₁S

lerdelimumabum

lerdelimumab

immunoglobulin G4, anti-(human transforming growth factor b2) (human monocloal CAT-152 γ 4-chain), disulfide with human monoclonal CAT-152 λ-chain, dimer

lérdelimumab

immunoglobuline G4, anti-(facteur de croissance transformant humain b2) (chaîne γ 4 de l'anticorps monoclonal humain CAT-152), dimère du disulfure avec la chaîne λ de l'anticorps monoclonal humain CAT-152

lerdelimumab

immunoglobulina G4, anti-(factor b2 de crecimiento transformador humano)(cadena γ 4 del anticuerpo monoclonal humano CAT-152), dimero del disulfuro con la cadena λ del anticuerpo monoclonal humano CAT-152

levmetamfetaminum

levmetamfetamine


(-)-(R)-N,α-dimethylphenethylamine

levmétamfétamine

(-)-(2R)-N-méthyl-1-phénylpropan-2-amine

levmetanfetamina

(-)-(R)-N,α-dimetilfenetilamina

C₁₀H₁₅N**lixivaptanum**

lixivaptan


3'-chloro-5-fluoro-4'-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-o-toluanilide

lixivaptan

N-[3-chloro-4-[(5H-pyrrolo[2,1-c][1,4]benzodiazépin-10(11H)-yl)carbonyl]phényl]-5-fluoro-2-méthylbenzamide

lixivaptán

3'-cloro-5-fluoro-4'-(5H-pirrolo[2,1-c][1,4]benzodiazepin-10(11H)-ilcarbonyl)-o-toluanilida

C₂₇H₂₁ClFN₃O₂

melevodopum

melevodopa


(-)-3,4-dihydroxy-L-phenylalanine, methyl ester

mélévodopa

(-)-(2*S*)-2-amino-3-(3,4-dihydroxyphényl)propanoate de méthyle

melevodopa

éster metílico de (-)-3,4-dihidroxi-L-fenilalanina

C₁₀H₁₃NO₄**meradimatum**


meradimate

p-menth-3-yl anthranilate

méradimate

2-aminobenzoate de 5-méthyl-2-(1-méthyléthyl)cyclohexyle

meradimato

antranilato de *p*-ment-3-iloC₁₇H₂₅NO₂**norelgestrominum**


norelgestromin

13-ethyl-17-hydroxy-18,19-dinor-17 α -pregn-4-en-20-yn-3-one oxime

norelgestromine

13-éthyl-17-hydroxy-18,19-dinor-17 α -prégn-4-én-20-yn-3-one oxime

norelgestromina

13-etil-17-hidroxi-18,19-dinor-17 α -pregn-4-en-20-in-3-ona oximaC₂₁H₂₉NO₂

octinoxatum


octinoxate

2-ethylhexyl *p*-methoxycinnamate

octinoxate

(E)-3-(4-méthoxyphényl)prop-2-énoate de (2*RS*)-2-éthylhexyle

octinoxato

p-metoxicinamato de 2-etilhexiloC₁₈H₂₆O₃**octisalatum**

octisalate


2-ethylhexyl salicylate

octisalate

2-hydroxybenzoate de (2*RS*)-2-éthylhexyle

octisalato

salicilato de 2-etilhexilo

C₁₅H₂₂O₃**opaviralinum**


opaviraline

isopropyl (*S*)-2-ethyl-7-fluoro-3,4-dihydro-3-oxo-1(2*H*)-quinoxalinecarboxylate

opaviraline

(2S)-2-éthyl-7-fluoro-3-oxo-3,4-dihydroquinoxaline-1(2*H*)-carboxylate de 1-méthyléthyle


opaviralina

(S)-2-etil-7-fluoro-3,4-dihidro-3-oxo-1(2*H*)-quinoxalinacarboxilato de isopropiloC₁₄H₁₇FN₂O₃

opebacanum	
opebacan	132-L-alanine-1-193-bactericidal/permeability-increasing protein (human)
opébacan	[132-L-alanine]-1-193-protéine humaine augmentant la perméabilité et à action bactéricide
opebacán	132-L-alanina-1-193-proteína(humana) bactericida/incrementadora de la permeabilidad

VNPGVVVRIS	QKGLDYASQQ	GTAALQKELK	RIKIPDYSDS
FKIKHLGKGH	YSFYSM DIRE	FQLPSSQISM	VPNVGLKFSI
SNANIKISGK	WKAQKRFLKM	SGNFDLSIEG	MSISADLKLK
SNPTSGKPTI	TASSCSSHIN	SVHVHISKSK	VGWLIQLFHK
KIESALRNKM	NSQVCEKVTN	SVSSELQPYF	QTL

oritavancinum	
oritavancin	(4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-méthyl- α -L-arabino-hexopyranosyl)-N ⁶ '-[p-(p-chlorophenyl)benzyl]vancomycin
oritavancine	acide (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-amino-3-C-méthyl-2,3,6-tridésoxy- α -L-arabino-hexopyranosyloxy)-3-(2-amino-2-oxoéthyl)-10,19-dichloro-44-[[2-O-[3-[[4'-chlorobiphényl-4-yl)méthyl]amino]-3-C-méthyl-2,3,6-tridésoxy- α -L-arabino-hexopyranosyl]- β -D-glucopyranosyl]oxy]-7,28,30,32-tétrahydroxy-6-[[[(2R)-4-méthyl-2-(méthylamino) pentanoyl]amino]-2,5,24,38,39-pentaoso-2,3,4,5,6,7,23,24,25,26,36,37,38,38a-tétradécahydro-8,11:18,21-diéthéno-23,36-(iminométhano)-22H-13,16:31,35-diméthéno-1H,13H-[1,6,9]oxadiazacyclohexadécino [4,5-m][10,2,16] benzoxadiazacyclotétracosène-26-carboxylique
oritavancina	(4' R)-22-O-(3-amino-2,3,6-tridesoxi-3-C-metil- α -L-arabino-hexopiranosil)-N ⁶ '-[p-(p-clorofenil)bencil]vancomicina

C₈₆H₉₇Cl₃N₁₀O₂₆

ozogamicinum
ozogamicin



methyl (1*R*,4*Z*,8*S*,13*E*)-13-[2-[[2-[[[*p*-(3-carbamoylpropoxy)- α -methylbenzylidene]hydrazino]carbonyl]-1,1-dimethylethyl]dithio]ethylidene]-8-[[4,6-dideoxy-4-[[[2,6-dideoxy-4-*S*-[4-[[6-deoxy-3-*O*-methyl- α -*L*-mannopyranosyl]oxy]-3-iodo-5,6-dimethoxy-*o*-toluoyl]-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-2-*O*-[2,4-dideoxy-4-(*N*-ethylacetamido)-3-*O*-methyl- α -*L*-threo-pentopyranosyl]- β -*D*-glucopyranosyl]oxy]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyne-10-carbamate

ozogamicine

[(1*R*,4*Z*,8*S*,13*E*)-8-[[2-*O*-[4-(acétyléthylamino)-3-*O*-méthyl-2,4-didésoxy- α -*L*-thréo-pentopyranosyl]-4-[[[4-*S*-[3-iodo-5,6-diméthoxy-2-méthyl-4-[[3-*O*-méthyl-6-désoxy- α -*L*-mannopyranosyl]oxy]benzoyl]-2,6-didésoxy-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-4,6-didésoxy- β -*D*-glucopyranosyl]oxy]-13-[2-[[3-[[1-[4-(4-amino-4-oxobutoxy)phényl]éthylidène]hydrazino]-1,1-diméthyl-3-oxopropyl]disulfanyl]éthylidène]-1-hydroxy-11-oxobicyclo[7.3.1] tridéca-4,9-diène-2,6-diyne-10-yl]carbamate de méthyle

ozogamicina

(1*R*,4*Z*,8*S*,13*E*)-13-[2-[[2-[[[*p*-(3-carbamoylpropoxy)- α -methylbenzylidene]hydrazino]carbonyl]-1,1-dimethylethyl]dithio]ethylidene]-8-[[4,6-dideoxy-4-[[[2,6-dideoxy-4-*S*-[4-[[6-deoxy-3-*O*-methyl- α -*L*-mannopyranosyl]oxy]-3-iodo-5,6-dimethoxy-*o*-toluoyl]-4-thio- β -*D*-ribo-hexopyranosyl]oxy]amino]-2-*O*-[2,4-dideoxy-4-(*N*-ethylacetamido)-3-*O*-methyl- α -*L*-threo-pentopyranosyl]- β -*D*-glucopyranosyl]oxy]-1-hydroxy-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyne-10-carbamate de metilo

**paliperidonum**

paliperidone



(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

palipéridone

(9*RS*)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)pipéridin-1-yl]éthyl]-9-hydroxy-2-méthyl-6,7,8,9-tétrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one

paliperidona

(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino]etil]-6,7,8,9-tetrahydro-9-hidroxi-2-metil-4*H*-pirido[1,2-*a*]pirimidin-4-ona

**pitavastatinum**

pitavastatin


(3*R*,5*S*,6*E*)-7-[2-cyclopropyl-4-(*p*-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid

pitavastatine

acide (6*E*)-(3*R*,5*S*)-7-[2-cyclopropyl-4-(4-fluorophényl)quinoléin-3-yl]-3,5-dihydroxyhept-6-énoïque

pitavastatina

ácido (3*R*,5*S*,6*E*)-7-[2-cicloclopropil-4-(*p*-fluorofenil)-3-quinolil]-3,5-dihidroxi-6-heptenoico

C₂₅H₂₄FNO₄**rimonabantum**


rimonabant

5-(*p*-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-*N*-piperidinopyrazole-3-carboxamide

rimonabant

5-(4-chlorophényl)-1-(2,4-dichlorophényl)-4-méthyl-*N*-(pipéridin-1-yl)-1*H*-pyrazole-3-carboxamide

rimonabant

5-(*p*-clorofenil)-1-(2,4-diclorofenil)-4-metil-*N*-piperidinopirazol-3-carboxamidaC₂₂H₂₁Cl₃N₄O**rostaporfinum**

rostaporfin



(OC-6-13)-dichloro[ethyl (18*RS*, 19*SR*)-3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato (2-)-*N*²³,*N*²⁴,*N*²⁵,*N*²⁶]tin

rostaporfine

(OC-6-13)-dichloro[(2*RS*,3*SR*)-2,7,12,17-tétraéthyl-3,8,13,18-tétraméthyl-2,3-dihydrocyclopenta[*a,f*]porphyrine-2¹-carboxylato(3-)-*N*²¹,*N*²²,*N*²³,*N*²⁴]stannate(2-) d'éthyle

rostaporfina

(OC-6-13)-dicloro[(18*RS*, 19*SR*)-3,4,20,21-tetradeshidro-4,9,14,19-tetraetil-18,19-dihidro-3,8,13,18-tetrametil-20-forbinacarboxilato de etilo (2-)-*N*²³,*N*²⁴,*N*²⁵,*N*²⁶]estaño

**rosuvastatinum**



rosuvastatin

(3*R*,5*S*,6*E*)-7-[4-(*p*-fluorophenyl)-6-isopropyl-2-(*N*-methylmethane sulfonamido)-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid

rosuvastatine

acide (3*R*,5*S*,6*E*)-7-[4-(4-fluorophényl)-6-(1-méthyléthyl)-2-[méthyl(méthylsulfonyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-énoïque

rosuvastatina

ácido (3*R*,5*S*,6*E*)-7-[4-(*p*-fluorofenil)-6-isopropil-2-(*N*-metilmetano sulfonamido)-5-pirimidinil]-3,5-dihidroxi-6-heptenoico**rotigotinum**



rotigotine

(-)-(*S*)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol

rotigotine

(-)-(6*S*)-6-[propyl[2-(thiophén-2-yl)éthyl]amino]-5,6,7,8-tétrahydronaphtalén-1-ol


rotigotina

(-)-(*S*)-5,6,7,8-tetrahidro-6-[propil[2-(2-tienil)etil]amino]-1-naftol


ruplizumabum ruplizumab	immunoglobulin G 1 (human-mouse monoclonal 5c8 γ 1-chain anti-human CD 40 ligand), disulfide with human-mouse monoclonal 5c8 κ -chain, dimer
ruplizumab	immunoglobuline G1 anti-(ligand CD 40 humain) (chaîne γ 1 de l'anticorps monoclonal de souris 5c8 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris 5c8 humanisé
ruplizumab	immunoglobulina G 1 anti-(ligando CD 40 humano) (cadena γ 1 del anticuerpo monoclonal hombre-ratón 5c8), dímero del disulfuro con la cadena κ del anticuerpo monoclonal hombre-ratón 5c8

sitaxentanum


sitaxentan	<i>N</i> -(4-chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)- <i>o</i> -tolyl]acetyl]-3-thiophenesulfonamide
sitaxentan	<i>N</i> -(4-chloro-3-méthylisoxazol-5-yl)-2-[[6-méthyl-1,3-benzodioxol-5-yl]acétyl]thiophène-3-sulfonamide
sitaxentán	<i>N</i> -(4-cloro-3-metil-5-isoxazolil)-2-[[4,5-(metilendioxi)- <i>o</i> -tolil]acetil]-3-tiofenosulfonamida

C₁₈H₁₅ClN₂O₆S₂**sulfamazonom**


sulfamazone	(<i>RS</i>)-(1,5-dimethyl-2-phenyl-3-oxo-2,3-dihydro-1 <i>H</i> -pyrazol-4-yl)[4-[(6-methoxy)pyridazin-3-yl]sulfamoyl]phenyl]amino]methanesulfonic acid
sulfamazone	acide (<i>RS</i>)-(1,5-diméthyl-2-phényl-3-oxo-2,3-dihydro-1 <i>H</i> -pyrazol-4-yl)[4-[(6-méthoxy)pyridazin-3-yl]sulfamoyl]phényl]amino]méthanesulfonique
sulfamazona	ácido (<i>RS</i>)-(1,5-dimetil-2-fenil-3-oxo-2,3-dihidro-1 <i>H</i> -pirazol-4-il)[4-[(6-metoxipiridazin-3-il)sulfamoil]fenil]amino]metanosulfónico

C₂₃H₂₄N₆O₇S₂and enantiomer
et énantiomère
y enantiómero


talaporfinum talaporfin	<i>N</i> -[[[(2 <i>S</i> ,3 <i>S</i>)-18-carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetraméthyl-8-vinylporphyrin-20-yl]acetyl]-L-aspartic acid
talaporfine	(2 <i>S</i>)-2-[[[(7 <i>S</i> ,8 <i>S</i>)-3-carboxy-7-(2-carboxyéthyl)-13-éthényl-18-éthyl-2,8,12,17-tétraméthyl-7,8-dihydroporphyrin-5-yl]acétyl]amino]butanedioïque
talaporfina	<i>N</i> -[[[(2 <i>S</i> ,3 <i>S</i>)-18-carboxi-2-(2-carboxietil)-13-etil-2,3-dihidro-3,7,12,17-tetrametil-8-vinilporfirin-20-il]acetil]-ácido-L-aspartico

C₃₈H₄₁N₅O₉

ticalopridum ticalopride	4-amino-5-chloro- <i>N</i> -[(3 <i>S</i> ,4 <i>R</i>)-3-methoxy-4-piperidyl]- <i>o</i> -anisamide
ticalopride	4-amino-5-chloro-2-méthoxy- <i>N</i> -[(3 <i>S</i> ,4 <i>R</i>)-3-méthoxypipéridin-4-yl]benzamide
ticaloprída	4-amino-5-cloro- <i>N</i> -[(3 <i>S</i> ,4 <i>R</i>)-3-metoxi-4-piperidil]- <i>o</i> -anisamida

C₁₄H₂₀ClN₃O₃

tolvaptanum tolvaptan	(±)-4'-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1 <i>H</i> -1-benzazepin-1-yl)carbonyl]- <i>o</i> -tolu- <i>m</i> -toluidide
tolvaptan	<i>N</i> -[4-[[[(5 <i>R</i>)-7-chloro-5-hydroxy-2,3,4,5-tétrahydro-1 <i>H</i> -1-benzazépin-1-yl]carbonyl]-3-méthylphényl]-2-méthylbenzamide
tolvaptán	(±)-4'-[(7-cloro-2,3,4,5-tetrahydro-5-hidroxi-1 <i>H</i> -1-benzazepin-1-il)carbonil]- <i>o</i> -tolu- <i>m</i> -toluidida

$C_{26}H_{25}ClN_2O_3$ **vilazodonum**

vilazodone


5-[4-[4-(5-cyanoindol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide

vilazodone

5-[4-[4-(5-cyano-1*H*-indol-3-yl)butyl]pipérazin-1-yl]benzofurane-2-carboxamide

vilazodona

5-[4-[4-(5-cianoindol-3-il)butil]-1-piperazinil]-2-benzofurancarboxamida

 $C_{26}H_{27}N_5O_2$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 14
(*WHO Chronicle, Vol. 28, No. 10, 1974*)

p. 1	<i>delete</i> amfebutamonum amfebutamone	<i>insert</i> bupropionum bupropion
------	---	--

Dénominations communes internationales recommandées (DCI Rec.): Liste 14
(*Chronique OMS, Vol. 28, No. 10, 1974*)

p. 1	<i>supprimer</i> amfebutamonum amfébutamone	<i>insérer</i> bupropionum bupropione
------	--	--

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 14
(*Crónica de la OMS, Vol. 28, No. 10, 1974*)

p. 1	<i>suprimase</i> amfebutamonum anfebutamona	<i>insértese</i> bupropionum bupropión
------	--	---

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30
(*Informacion farmaceutica de la OMS, Vol. 4, No. 3, 1990*)

p. 5	<i>suprimase</i> enalquireno	<i>insértese</i> enalkireno
------	---------------------------------	--------------------------------

Recommended International Nonproprietary Names (Rec. INN): List 42
Dénominations communes internationales recommandées (DCI Rec.): Liste 42
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 42
(*WHO Drug Information, Vol. 13, No. 3, 1999*)

p. 198	<i>delete/supprimer/suprimase</i> olmesartanum olmesartan olmésartan olmesartán	<i>insert/insérer/insértese</i> olmesartanum medoxomilum olmesartan medoxomil olmésartan médoxomil olmesartán medoxmilo
--------	--	--

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

- p. 184 **adalimumabum**
adalimumab *sustitúyase la descripción por la siguiente:*
inmunoglobulina G1 (anti-factor α de necrosis tumoral humano) (cadena pesada del anticuerpo monoclonal humano D2E7), dímero del disulfuro con la cadena κ del anticuerpo D2E7 monoclonal humano
- p. 185 **amiglumidum**
amiglumida *sustitúyase la descripción por la siguiente:*
ácido (R)-4-(2-naftamido)-N,N-dipentilglutarámico
- p. 193 **evernimicinum**
evernimicina *sustitúyase la descripción por la siguiente:*
O-2,3,6-tridesoxi-3-C-metil-4-O-metil-3-nitro- α -L-arabino-hexopiranosil-(1 \rightarrow 3)-O-2,6-didesoxi-4-O-(3,5-dicloro-6-metoxi-4,2-cresotoil)- β -D-arabino-hexopiranosil-(1 \rightarrow 4)-O-(1R)-2,6-didesoxi-D-arabino-hexopiranosilideno-(1 \rightarrow 3-4)-O-6-desoxi-3-C-metil- β -D-manopiranosil-(1 \rightarrow 3)-O-6-desoxi-4-O-metil- β -D-galactopiranosil-(1 \rightarrow 4)-2,6-di-O-metil- β -D-manopiranosido de O-(1R)-2,3-O-metileno-4-O-(6-metil- β -resorciloil)-D-xilopiranosilideno-(1 \rightarrow 3-4)- α -L-lixopiranosilo
- p. 196 **irofulvenum**
irofulveno *sustitúyase la descripción por la siguiente:*
(R)-6'-hidroxi-3'-(hidroximetil)-2',4',6'-trimetilespiro[ciclopropano-1,5'-[5H]inden]-7'(6'H)-ona
- p. 201 **posaconazolum**
posaconazol *sustitúyase la descripción por la siguiente:*
4-[p-[4-[p-[[[3R,5R]-5-(2,4-difluorofenil)tetrahydro-5-(1H-1,2,4-triazol-1-ilmetil)-3-furil]metoxi]fenil]-1-piperazinil]fenil]-1-[(1S,2S)-1-etil-2-hidroxiopropil]- Δ^2 -1,2,4-triazolin-5-ona

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

1

2

3

4